UDC

611.018.74+612.13

DOI

10.37482/2687-1491-Z257

Authors

Galina N. Kostrova* ORCID: https://orcid.org/0000-0002-3132-6439
Natalya A. Bebyakova* ORCID: https://orcid.org/0000-0002-9346-1898
Anna V. Khromova* ORCID: https://orcid.org/0000-0001-6440-4061
Yuliya A. Popova* ORCID: https://orcid.org/0000-0003-1684-6636
Aleksandra A. Murashkina * ORCID: https://orcid.org/0000-0002-4708-5203
*Northern State Medical University (Arkhangelsk, Russia)

Abstract

This review aims to examine the relevant current information about novel markers of endothelial dysfunction and to systematize it. The following electronic databases were searched: PubMed, CyberLeninka, eLIBRARY.RU and ScienceDirect. We selected 28 articles published between January 1, 2014 and August 30, 2024. Inclusion criteria were open access and Russian or English language. Exclusion criteria were low informational value and old data. The following keywords in Russian and English were used: endothelium, endothelial dysfunction, modern markers of endothelial dysfunction, endocan, endoglin, galectin-3, endothelial progenitor cells, big ET-1 and endothelial extracellular vesicles). We divided novel laboratory markers of endothelial dysfunction into two groups: markers produced by the endothelium and molecules that regulate endothelial activation/function. In addition, the article presents the origination mechanisms of sVCAM-1, endocan, endoglin, galectin-3, endothelial progenitor cells, endothelin, big ET-1 and endothelial extracellular vesicles. Their role in endothelial dysfunction is described, as well as their association with some common pathologies, primarily cardiovascular diseases and cancer. Further, we reviewed the most effective diagnostic methods for these biomarkers in modern clinical diagnostic laboratories. Due to the fact that the majority of these markers are not strictly specific for certain diseases, but characterize the state of the endothelium as a whole, there is an urgent need for new markers of endothelial dysfunction and for a comprehensive use of the already studied biomolecules. Determining the blood levels of the molecules in question can help in timely primary prevention, risk assessment and selection of optimal treatment and diagnostic tactics.

Keywords

biomarkers of endothelial dysfunction, sVCAM-1, endocan, endoglin, galectin-3, endothelial progenitor cells, big ET-1, endothelial extracellular vesicles

References

1. Shabrov A.V., Galenko A.S., Uspensky Yu.P., Loseva K.A. Methods for Diagnosing Endothelial Dysfunction. Bull. Sib. Med., 2021, vol. 20, no. 2, pp. 202–209. https://doi.org/10.20538/1682-0363-2021-2-202-209
2. Lee D.D., Schwarz M.A. Cell-Cell Communication Breakdown and Endothelial Dysfunction. Crit. Care Clin., 2020, vol. 36, no. 2, pp. 189–200. https://doi.org/10.1016/j.ccc.2019.11.001
3. Alekperova A.N., Misnik A.V. Novye markery otsenki endotelial’noy disfunktsii [Novel Markers for Assessing Endothelial Dysfunction]. Forcipe, 2020, vol. 3, no. S1, p. 342.
4. Abdurakhmanov Z.M., Umarov B.Y., Abdurakhmanov M.M. Novel Biomarkers of Endothelial Dysfunction in Cardiovascular Diseases. Ration. Pharmacother. Cardiol., 2021, vol. 17, no. 4, pp. 612–618 (in Russ.). https://doi.org/10.20996/1819-6446-2021-08-08
5. Matheus A.S.M., da Matta M.F.B., Clemente E.L.S., Rodrigues M.L.G., Valença D.C.T., Drummond K.R.G., Gomes M.B. Biochemical and Clinical Markers of Endothelial Dysfunction Do Not Outweigh Traditional Risk Factors for the Presence of Diabetic Retinopathy in Patients with Type 1 Diabetes. Diabetol. Metab. Syndr., 2022, vol. 14, no. 1. Art. no. 141. https://doi.org/10.1186/s13098-022-00912-y
6. Podzolkov V.I., Pokrovskaya A.E., Vanina D.D., Shvedov I.I. sVCAM-1 as a Marker of Endothelial Dysfunction Associated with Severe Course of a Novel Coronavirus Infection (COVID-19). Ration. Pharmacother. Cardiol., 2023, vol. 19, no. 2, pp. 134–142 (in Russ.). https://doi.org/10.20996/1819-6446-2023-03-08
7. Hong H.-J., Oh Y.-I., Park S.-M., An J.-H., Kim T.-H., Chae H.-K., Seo K.-W., Youn H.-Y. Evaluation of Endothelial Cell-Specific Molecule-1 as a Biomarker of Glycocalyx Damage in Canine Myxomatous Mitral Valve Disease. BMC Vet. Res., 2022, vol. 18, no. 1. Art. no. 261. https://doi.org/10.1186/s12917-022-03344-y
8. Lu J., Liu Q., Zhu L., Liu Y., Zhu X., Peng S., Chen M., Li P. Endothelial Cell-Specific Molecule 1 Drives Cervical Cancer Progression. Cell Death Dis., 2022, vol. 13, no. 12. Art. no. 1043. https://doi.org/10.1038/s41419-022-05501-5
9. Chen J., Jiang L., Yu X.-H., Hu M., Zhang Y.-K., Liu X., He P., Ouyang X. Endocan: A Key Player of Cardiovascular Disease. Front. Cardiovasc. Med., 2022, vol. 8. Art. no. 798699. https://doi.org/10.3389/fcvm.2021.798699
10. Alieva A.M., Reznik E.V., Baykova I.E., Teplova N.V., Makeeva L.M., Voronkova K.V., Khadzhieva N.Kh., Modestova A.V., Totolyan G.G., Valiev R.K., Li A.M., Kotikova I.A., Nikitin I.G. Endocan Is a Key Player in Cardiovascular Disease: A Review. Consilium medicum, 2023, vol. 25, no. 1, pp. 20–28. https://doi.org/10.26442/20751753.2023.1.202079
11. Rathouska J., Jezkova K., Nemeckova I., Nachtigal P. Soluble Endoglin, Hypercholesterolemia and Endothelial Dysfunction. Atherosclerosis, 2015, vol. 243, no. 2, pp. 383–388. https://doi.org/10.1016/j.atherosclerosis.2015.10.003
12. Zhang L., Li X., Zhou C., You Z., Zhang J., Cao G. The Diagnosis Values of Serum STAT4 and sEng in Preeclampsia. J. Clin. Lab. Anal., 2020, vol. 34, no. 2. Art. no. e23073. https://doi.org/10.1002/jcla.23073
13. Gorbacheva A.M., Bibik E.E., Dobreva E.A., Elfimova A.R., Eremkina A.K., Mokrysheva N.G. Soluble Endoglin as a Perspective Marker of Endothelial Dysfunction in Patients with Primary Hyperparathyroidism: A Pilot Study. Obes. Metab., 2022, vol. 19, no. 4, pp. 358–368 (in Russ.). https://doi.org/10.14341/omet12923
14. Rossi E., Bernabeu C. Novel Vascular Roles of Human Endoglin in Pathophysiology. J. Thromb. Haemost., 2023, vol. 21, no. 9, pp. 2327–2338. https://doi.org/10.1016/j.jtha.2023.06.007
15. Scioli M.G., Storti G., D’Amico F., Rodríguez Guzmán R., Centofanti F., Doldo E., Céspedes Miranda E.M., Orlandi A. Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic Targets. J. Clin. Med., 2020, vol. 9, no. 6. Art. no. 1995. https://doi.org/10.3390/jcm9061995
16. Schoonderwoerd M.J.A., Goumans M.-J.T.H., Hawinkels L.J.A.C. Endoglin: Beyond the Endothelium. Biomolecules, 2020, vol. 10, no. 2. Art. no. 289. https://doi.org/10.3390/biom10020289
17. Baldassarre M.P.A., Pipino C., Pandolfi A., Consoli A., Di Pietro N., Formoso G. Old and New Biomarkers Associated with Endothelial Dysfunction in Chronic Hyperglycemia. Oxid. Med. Cell. Longev., 2021, vol. 2021. Art. no. 7887426. https://doi.org/10.1155/2021/7887426
18. Lia G., Giaccone L., Leone S., Bruno B. Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role? Front. Immunol., 2021, vol. 12. Art. no. 641427. https://doi.org/10.3389/fimmu.2021.641427
19. Berezin A.E., Kremzer A.A., Martovitskaya Y.V., Samura T.A., Berezina T.A. The Predictive Role of Circulating Microparticles in Patients with Chronic Heart Failure. BBA Clin., 2014, vol. 3, pp. 18–24. https://doi.org/10.1016/j.bbacli.2014.11.006
20. Peyter A.-C., Armengaud J.-B., Guillot E., Yzydorczyk C. Endothelial Progenitor Cells Dysfunctions and Cardiometabolic Disorders: From Mechanisms to Therapeutic Approaches. Int. J. Mol. Sci., 2021, vol. 22, no. 13. Art. no. 6667. https://doi.org/10.3390/ijms22136667
21. Alieva A.M., Chirkova N.N., Pinchuk T.V., Andreeva O.N., Pivovarov V.Yu. Endothelines and Cardiovascular Pathology. Russ. J. Cardiol., 2014, no. 11, pp. 83–87 (in Russ.). https://doi.org/10.15829/1560-4071-2014-11-83-87
22. Golivets T.P., Dubonosova D.G., Osipova O.A., Petrova G.D. Effekty endotelina-1 v razvitii i progressirovanii metabolicheskogo sindroma i drugikh sotsial’no znachimykh neinfektsionnykh zabolevaniy (obzor literatury) [The Effects of Endothelin 1 in the Development and Progression of Metabolic Syndrome and Socially Significant NonCommunicable Diseases (Review of Literature)]. Aktual’nye problemy meditsiny, 2017, no. 19, iss. 39, pp. 5–19.
23. Iglarz M., Clozel M. Mechanisms of ET-1-Induced Endothelial Dysfunction. J. Cardiovasc. Pharmacol., 2007, vol. 50, no. 6, pp. 621–628. https://doi.org/10.1097/fjc.0b013e31813c6cc3
24. Lyu S.-Q., Zhu J., Wang J., Wu S., Zhang H., Shao X.-H., Yang Y.-M. Plasma Big Endothelin-1 Levels and Long-Term Outcomes in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Front. Cardiovasc. Med., 2022, vol. 9. Art. no. 756082. https://doi.org/10.3389/fcvm.2022.756082
25. Dong R., Zhang M., Hu Q., Zheng S., Soh A., Zheng Y., Yuan H. Galectin-3 as a Novel Biomarker for Disease Diagnosis and a Target for Therapy (Review). Int. J. Mol. Med., 2018, vol. 41, no. 2, pp. 599–614. https://doi.org/10.3892/ijmm.2017.3311
26. Chaulin A.M., Grigor’eva Yu.V. Galektin-3 kak prognosticheskiy biomarker serdechnoy nedostatochnosti (obzor literatury) [Galectin-3 as a Prognostic Biomarker of Heart Failure (a Literature Review)]. Mezhdunarodnyy nauchno-issledovatel’skiy zhurnal, 2021, no. 2–3, pp. 55–60. https://doi.org/10.23670/IRJ.2021.103.2.072
27. Pang Z.-D., Sun X., Bai R.-Y., Han M.-Z., Zhang Y.-J., Wu W., Zhang Y., Lai B.-C., Zhang Y., Wang Y., Du X.-J., Deng X.-L. YAP-Galectin-3 Signaling Mediates Endothelial Dysfunction in Angiotensin II-Induced Hypertension in Mice. Cell. Mol. Life Sci., 2023, vol. 80, no. 2. Art. no. 38. https://doi.org/10.1007/s00018-022-04623-5
28. Ou H.-C., Chou W.-C., Hung C.-H., Chu P.-M., Hsieh P.-L., Chan S.-H., Tsai K.-L. Galectin-3 Aggravates Ox-LDL-Induced Endothelial Dysfunction Through LOX-1 Mediated Signaling Pathway. Environ. Toxicol., 2019, vol. 34, no. 7, pp. 825–835. https://doi.org/10.1002/tox.22750